The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
<h4>Background</h4>Tuberculosis (TB) is preventable and curable but eliminating it has proven challenging. Safe and effective TB vaccines that can rapidly reduce disease burden are essential for achieving TB elimination. We assessed future costs, cost-savings, and cost-effectiveness of i...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS Medicine |
| Online Access: | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004155&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850134276327079936 |
|---|---|
| author | Allison Portnoy Rebecca A Clark Matthew Quaife Chathika K Weerasuriya Christinah Mukandavire Roel Bakker Arminder K Deol Shelly Malhotra Nebiat Gebreselassie Matteo Zignol So Yoon Sim Raymond C W Hutubessy Inés Garcia Baena Nobuyuki Nishikiori Mark Jit Richard G White Nicolas A Menzies |
| author_facet | Allison Portnoy Rebecca A Clark Matthew Quaife Chathika K Weerasuriya Christinah Mukandavire Roel Bakker Arminder K Deol Shelly Malhotra Nebiat Gebreselassie Matteo Zignol So Yoon Sim Raymond C W Hutubessy Inés Garcia Baena Nobuyuki Nishikiori Mark Jit Richard G White Nicolas A Menzies |
| author_sort | Allison Portnoy |
| collection | DOAJ |
| description | <h4>Background</h4>Tuberculosis (TB) is preventable and curable but eliminating it has proven challenging. Safe and effective TB vaccines that can rapidly reduce disease burden are essential for achieving TB elimination. We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.<h4>Methods and findings</h4>We developed a system of epidemiological and economic models, calibrated to demographic, epidemiological, and health service data in 105 LMICs. For each country, we assessed the likely future course of TB-related outcomes under several vaccine introduction scenarios, compared to a "no-new-vaccine" counterfactual. Vaccine scenarios considered 2 vaccine product profiles (1 targeted at infants, 1 at adolescents/adults), both assumed to prevent progression to active TB. Key economic inputs were derived from the Global Health Cost Consortium, World Health Organization (WHO) patient cost surveys, and the published literature. We estimated the incremental impact of vaccine introduction for a range of health and economic outcomes. In the base-case, we assumed a vaccine price of $4.60 and used a 1× per-capita gross domestic product (GDP) cost-effectiveness threshold (both varied in sensitivity analyses). Vaccine introduction was estimated to require substantial near-term resources, offset by future cost-savings from averted TB burden. From a health system perspective, adolescent/adult vaccination was cost-effective in 64 of 105 LMICs. From a societal perspective (including productivity gains and averted patient costs), adolescent/adult vaccination was projected to be cost-effective in 73 of 105 LMICs and cost-saving in 58 of 105 LMICs, including 96% of countries with higher TB burden. When considering the monetized value of health gains, we estimated that introduction of an adolescent/adult vaccine could produce $283 to 474 billion in economic benefits by 2050. Limited data availability required assumptions and extrapolations that may omit important country-level heterogeneity in epidemiology and costs.<h4>Conclusions</h4>TB vaccination would be highly impactful and cost-effective in most LMICs. Further efforts are needed for future development, adoption, and implementation of novel TB vaccines. |
| format | Article |
| id | doaj-art-aa3e5eed9e6749f0bee57ba53643893c |
| institution | OA Journals |
| issn | 1549-1277 1549-1676 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Medicine |
| spelling | doaj-art-aa3e5eed9e6749f0bee57ba53643893c2025-08-20T02:31:44ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762023-01-01201e100415510.1371/journal.pmed.1004155The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.Allison PortnoyRebecca A ClarkMatthew QuaifeChathika K WeerasuriyaChristinah MukandavireRoel BakkerArminder K DeolShelly MalhotraNebiat GebreselassieMatteo ZignolSo Yoon SimRaymond C W HutubessyInés Garcia BaenaNobuyuki NishikioriMark JitRichard G WhiteNicolas A Menzies<h4>Background</h4>Tuberculosis (TB) is preventable and curable but eliminating it has proven challenging. Safe and effective TB vaccines that can rapidly reduce disease burden are essential for achieving TB elimination. We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.<h4>Methods and findings</h4>We developed a system of epidemiological and economic models, calibrated to demographic, epidemiological, and health service data in 105 LMICs. For each country, we assessed the likely future course of TB-related outcomes under several vaccine introduction scenarios, compared to a "no-new-vaccine" counterfactual. Vaccine scenarios considered 2 vaccine product profiles (1 targeted at infants, 1 at adolescents/adults), both assumed to prevent progression to active TB. Key economic inputs were derived from the Global Health Cost Consortium, World Health Organization (WHO) patient cost surveys, and the published literature. We estimated the incremental impact of vaccine introduction for a range of health and economic outcomes. In the base-case, we assumed a vaccine price of $4.60 and used a 1× per-capita gross domestic product (GDP) cost-effectiveness threshold (both varied in sensitivity analyses). Vaccine introduction was estimated to require substantial near-term resources, offset by future cost-savings from averted TB burden. From a health system perspective, adolescent/adult vaccination was cost-effective in 64 of 105 LMICs. From a societal perspective (including productivity gains and averted patient costs), adolescent/adult vaccination was projected to be cost-effective in 73 of 105 LMICs and cost-saving in 58 of 105 LMICs, including 96% of countries with higher TB burden. When considering the monetized value of health gains, we estimated that introduction of an adolescent/adult vaccine could produce $283 to 474 billion in economic benefits by 2050. Limited data availability required assumptions and extrapolations that may omit important country-level heterogeneity in epidemiology and costs.<h4>Conclusions</h4>TB vaccination would be highly impactful and cost-effective in most LMICs. Further efforts are needed for future development, adoption, and implementation of novel TB vaccines.https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004155&type=printable |
| spellingShingle | Allison Portnoy Rebecca A Clark Matthew Quaife Chathika K Weerasuriya Christinah Mukandavire Roel Bakker Arminder K Deol Shelly Malhotra Nebiat Gebreselassie Matteo Zignol So Yoon Sim Raymond C W Hutubessy Inés Garcia Baena Nobuyuki Nishikiori Mark Jit Richard G White Nicolas A Menzies The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study. PLoS Medicine |
| title | The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study. |
| title_full | The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study. |
| title_fullStr | The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study. |
| title_full_unstemmed | The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study. |
| title_short | The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study. |
| title_sort | cost and cost effectiveness of novel tuberculosis vaccines in low and middle income countries a modeling study |
| url | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004155&type=printable |
| work_keys_str_mv | AT allisonportnoy thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT rebeccaaclark thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT matthewquaife thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT chathikakweerasuriya thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT christinahmukandavire thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT roelbakker thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT arminderkdeol thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT shellymalhotra thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT nebiatgebreselassie thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT matteozignol thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT soyoonsim thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT raymondcwhutubessy thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT inesgarciabaena thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT nobuyukinishikiori thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT markjit thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT richardgwhite thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT nicolasamenzies thecostandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT allisonportnoy costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT rebeccaaclark costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT matthewquaife costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT chathikakweerasuriya costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT christinahmukandavire costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT roelbakker costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT arminderkdeol costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT shellymalhotra costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT nebiatgebreselassie costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT matteozignol costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT soyoonsim costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT raymondcwhutubessy costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT inesgarciabaena costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT nobuyukinishikiori costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT markjit costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT richardgwhite costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy AT nicolasamenzies costandcosteffectivenessofnoveltuberculosisvaccinesinlowandmiddleincomecountriesamodelingstudy |